Roche scrutinized by UK watchdog over 'misleading' Rozlytrek promotional website
The UK’s Prescription Medicines Code of Practice Authority (PMCPA) has ruled that a Roche webpage for its cancer medication Rozlytrek misled healthcare professionals.
The allegations stemmed from an anonymous complaint filed by a self-proclaimed health professional who argued that Roche’s resources website left out important information around potential dose reductions and discontinuations for certain patients being monitored on the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.